Trials / Terminated
TerminatedNCT02247531
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 975 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lampalizumab | 10 mg dose of lampalizumab administered intravitreally. |
| OTHER | Sham Comparator | A sham injection is a procedure that mimics an intravitreal injection of lampalizumab. |
Timeline
- Start date
- 2014-10-06
- Primary completion
- 2018-01-23
- Completion
- 2018-01-23
- First posted
- 2014-09-25
- Last updated
- 2019-10-15
- Results posted
- 2019-03-14
Locations
153 sites across 22 countries: United States, Argentina, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Peru, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02247531. Inclusion in this directory is not an endorsement.